Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
Identifieur interne : 000524 ( Pmc/Curation ); précédent : 000523; suivant : 000525Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
Auteurs : Juan Simon Rico-Mesa [États-Unis] ; Averi White [États-Unis] ; Allen S. Anderson [États-Unis]Source :
- Current Cardiology Reports [ 1523-3782 ] ; 2020.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.
Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated.
Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change.
Url:
DOI: 10.1007/s11886-020-01291-4
PubMed: 32291526
PubMed Central: 7154066
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000524
Links to Exploration step
PMC:7154066Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB</title>
<author><name sortKey="Rico Mesa, Juan Simon" sort="Rico Mesa, Juan Simon" uniqKey="Rico Mesa J" first="Juan Simon" last="Rico-Mesa">Juan Simon Rico-Mesa</name>
<affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.215352.2</institution-id>
<institution-id institution-id-type="ISNI">0000000121845633</institution-id>
<institution>Department of Medicine,</institution>
<institution>University of Texas Health San Antonio,</institution>
</institution-wrap>
San Antonio, TX 78229 USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>San Antonio</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="White, Averi" sort="White, Averi" uniqKey="White A" first="Averi" last="White">Averi White</name>
<affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.215352.2</institution-id>
<institution-id institution-id-type="ISNI">0000000121845633</institution-id>
<institution>Department of Medicine,</institution>
<institution>University of Texas Health San Antonio,</institution>
</institution-wrap>
San Antonio, TX 78229 USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>San Antonio</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Anderson, Allen S" sort="Anderson, Allen S" uniqKey="Anderson A" first="Allen S." last="Anderson">Allen S. Anderson</name>
<affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.215352.2</institution-id>
<institution-id institution-id-type="ISNI">0000000121845633</institution-id>
<institution>Department of Medicine, Division of Cardiovascular Diseases,</institution>
<institution>University of Texas Health San Antonio,</institution>
</institution-wrap>
7703 Floyd Curl Drive, MC 7872, San Antonio, TX 78229 USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>7703 Floyd Curl Drive, MC 7872, San Antonio</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32291526</idno>
<idno type="pmc">7154066</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154066</idno>
<idno type="RBID">PMC:7154066</idno>
<idno type="doi">10.1007/s11886-020-01291-4</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000524</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000524</idno>
<idno type="wicri:Area/Pmc/Curation">000524</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000524</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB</title>
<author><name sortKey="Rico Mesa, Juan Simon" sort="Rico Mesa, Juan Simon" uniqKey="Rico Mesa J" first="Juan Simon" last="Rico-Mesa">Juan Simon Rico-Mesa</name>
<affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.215352.2</institution-id>
<institution-id institution-id-type="ISNI">0000000121845633</institution-id>
<institution>Department of Medicine,</institution>
<institution>University of Texas Health San Antonio,</institution>
</institution-wrap>
San Antonio, TX 78229 USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>San Antonio</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="White, Averi" sort="White, Averi" uniqKey="White A" first="Averi" last="White">Averi White</name>
<affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.215352.2</institution-id>
<institution-id institution-id-type="ISNI">0000000121845633</institution-id>
<institution>Department of Medicine,</institution>
<institution>University of Texas Health San Antonio,</institution>
</institution-wrap>
San Antonio, TX 78229 USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>San Antonio</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Anderson, Allen S" sort="Anderson, Allen S" uniqKey="Anderson A" first="Allen S." last="Anderson">Allen S. Anderson</name>
<affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.215352.2</institution-id>
<institution-id institution-id-type="ISNI">0000000121845633</institution-id>
<institution>Department of Medicine, Division of Cardiovascular Diseases,</institution>
<institution>University of Texas Health San Antonio,</institution>
</institution-wrap>
7703 Floyd Curl Drive, MC 7872, San Antonio, TX 78229 USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>7703 Floyd Curl Drive, MC 7872, San Antonio</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Current Cardiology Reports</title>
<idno type="ISSN">1523-3782</idno>
<idno type="eISSN">1534-3170</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Purpose of Review</title>
<p id="Par1">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.</p>
</sec>
<sec><title>Recent Findings</title>
<p id="Par2">Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated.</p>
</sec>
<sec><title>Summary</title>
<p id="Par3">Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Watkins, J" uniqKey="Watkins J">J Watkins</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Cardiol Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Cardiol Rep</journal-id>
<journal-title-group><journal-title>Current Cardiology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1523-3782</issn>
<issn pub-type="epub">1534-3170</issn>
<publisher><publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">32291526</article-id>
<article-id pub-id-type="pmc">7154066</article-id>
<article-id pub-id-type="publisher-id">1291</article-id>
<article-id pub-id-type="doi">10.1007/s11886-020-01291-4</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Hot Topic</subject>
</subj-group>
</article-categories>
<title-group><article-title>Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Rico-Mesa</surname>
<given-names>Juan Simon</given-names>
</name>
<address><email>mesajs@uthscsa.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>White</surname>
<given-names>Averi</given-names>
</name>
<address><email>whitea4@livemail.uthscsa.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Anderson</surname>
<given-names>Allen S.</given-names>
</name>
<address><email>Andersona4@uthscsa.edu</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label>
<institution-wrap><institution-id institution-id-type="GRID">grid.215352.2</institution-id>
<institution-id institution-id-type="ISNI">0000000121845633</institution-id>
<institution>Department of Medicine,</institution>
<institution>University of Texas Health San Antonio,</institution>
</institution-wrap>
San Antonio, TX 78229 USA</aff>
<aff id="Aff2"><label>2</label>
<institution-wrap><institution-id institution-id-type="GRID">grid.215352.2</institution-id>
<institution-id institution-id-type="ISNI">0000000121845633</institution-id>
<institution>Department of Medicine, Division of Cardiovascular Diseases,</institution>
<institution>University of Texas Health San Antonio,</institution>
</institution-wrap>
7703 Floyd Curl Drive, MC 7872, San Antonio, TX 78229 USA</aff>
</contrib-group>
<pub-date pub-type="epub"><day>14</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub"><year>2020</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<elocation-id>31</elocation-id>
<permissions><copyright-statement>© Springer Science+Business Media, LLC, part of Springer Nature 2020</copyright-statement>
<license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
</license>
</permissions>
<abstract id="Abs1"><sec><title>Purpose of Review</title>
<p id="Par1">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.</p>
</sec>
<sec><title>Recent Findings</title>
<p id="Par2">Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated.</p>
</sec>
<sec><title>Summary</title>
<p id="Par3">Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change.</p>
</sec>
</abstract>
<kwd-group xml:lang="en"><title>Keywords</title>
<kwd>COVID-19</kwd>
<kwd>SARS-COV 2</kwd>
<kwd>ACEI</kwd>
<kwd>ARB</kwd>
<kwd>ACE2 receptor</kwd>
</kwd-group>
<custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000524 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000524 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:7154066 |texte= Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:32291526" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |